Content area

|
|

Behandling af svær astma med biologiske lægemidler hos børn og unge

Forfatter(e)
Katrine Bredsdorff Spangenberg1, Uffe Bødtger2, 3, Kirsten Skamstrup Hansen1, 4 & Bo Chawes1, 5
1) Børne- og Ungeafdelingen, Herlev og Gentofte Hospital 2) Lungemedicinsk Afdeling, Næstved Sygehus 3) Lungemedicinsk Afdeling, Sjællands Universitetshospital Roskilde 4) Klinik for Allergi, Herlev og Gentofte Hospital 5) Dansk BørneAstma Center/COPSAC, Herlev og Gentofte Hospital

Ugeskr Læger 2019;181:V05180364

Reference: 
Ugeskr Læger 2019;181:V05180364

Katrine Bredsdorff Spangenberg, Uffe Bødtger, Kirsten Skamstrup Hansen
& Bo Chawes:

Biological drugs for treatment of children and adolescents with severe asthma

Ugeskr Læger 2019;181:V05180364

Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Benny Andreasson | 23/08
1 Kommentar
af Sven Felsby | 20/08
1 Kommentar
af Christian Visby Carlsen | 20/08
8 kommentarer
af Jørn Rosborg | 18/08
2 kommentarer
af Kasper Broby Eckert | 17/08
3 kommentarer
af Pal Bela Szecsi | 16/08
1 Kommentar
af Michael Prangsgaard Møller | 16/08
2 kommentarer